Table 1. . Clinical trials evaluating adjuvant tyrosine kinase and mTOR inhibition for renal cell carcinoma.

Trial	Status	Treatments compared	Stage for inclusion	Histology	Primary outcome	Ref.
ASSURE	Reported	Sunitinib, sorafenib or placebo for 54 weeks	pT1b (grade 3–4), pT2-4 or TanyN1	Clear cell or nonclear cell	DFS; no difference	[8]
S-TRAC	Reported	Sunitinib or placebo for 1 year	pT3-4 or TanyN1	Clear cell only	DFS; improved (HR: 0.76 [0.59–0.98]; p = 0.03) for sunitinib	[10]
PROTECT	Reported	Pazopanib or placebo for 1 year	pT2 (grade 3–4), pT3-4, or TanyN1	Clear cell or predominantly clear cell	DFS; no difference	[9]
ATLAS	Reported	Axitinib or placebo for 1–3 years	pT2 or TanyN1	Clear cell or predominantly clear cell	DFS; no difference, stopped early for futility	[7]
SORCE	Ongoing	Sorafenib (3 years), sorafenib (1 year) or placebo	Leibovich score 3–11	Clear cell or nonclear cell	DFS; ongoing	NCT00492258
EVEREST	Ongoing	Everolimus or placebo for 54 weeks	pT1b (grade 3–4), pT2-4 or TanyN1	Clear cell or nonclear cell	RFS; ongoing	NCT01120249

DFS: Disease-free survival; HR: Hazard ratio; RFS: Recurrence-free survival.